Schulze, Marco H.

[["dc.bibliographiccitation.journal","Frontiers in Microbiology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Taverne-Ghadwal, Liliane"],["dc.contributor.author","Kuhns, Martin"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Mbaitolum, Weina Joseph"],["dc.contributor.author","Kersch, Lydia"],["dc.contributor.author","Weig, Michael"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Groß, U."],["dc.date.accessioned","2022-04-01T10:00:45Z"],["dc.date.available","2022-04-01T10:00:45Z"],["dc.date.issued","2022"],["dc.description.abstract","Oral candidiasis remains a common problem in HIV-infected individuals, especially in sub-Saharan Africa. Here, we performed the first study in Chad on the prevalence of oral yeasts carriage and oral candidiasis in HIV-positive subjects from southern Chad and analyzed the influence of HAART, CD4 + T-cell numbers, and antimycotics in 589 patients. These patients were recruited from a specialized medical center for HIV patients in Sarh and from a rural medical health dispensary in the vicinity, including a total of 384 HIV-positive and 205 HIV-negative individuals. Yeasts obtained from oral specimen were identified by MALDI-TOF MS and their antifungal susceptibility profiles determined. The overall prevalence of yeast colonization and symptomatic oral candidiasis in HIV-infected patients was 25.1%. The prevalence of oral candidiasis was higher in untreated than in HAART-treated HIV-positive patients (16% vs. 2%; p  < 0.01). Oral candidiasis was furthermore associated with high fungal burdens of Candida albicans and a CD4 + T-cell number <200/μl. A shift toward non -albicans Candida species was observed under nucleoside-based HAART therapy. Azole antifungal drug resistance was only observed for the intrinsically resistant species Candida krusei and Candida glabrata . Prevalence of oral candidiasis in the studied area was very low. The species distribution was similar to other countries around the world, with C. albicans being dominant. Candida dubliniensis was not isolated. Nucleoside-based HAART therapy significantly reduced oral colonization as well as occurrence of oral candidiasis caused by C. albicans and led to a species shift toward non- albicans species. Antifungal resistance was not yet a concern in Chad."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fmicb.2022.844069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105503"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1664-302X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","916"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Emerging Infectious Diseases"],["dc.bibliographiccitation.lastpage","919"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Janssen, Hauke"],["dc.contributor.author","Janssen, Iryna"],["dc.contributor.author","Cooper, Paul"],["dc.contributor.author","Kainyah, Clemens"],["dc.contributor.author","Pellio, Theresia"],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Monnheimer, Mathieu"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2020-12-10T18:44:07Z"],["dc.date.available","2020-12-10T18:44:07Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3201/eid2405.171506"],["dc.identifier.eissn","1080-6059"],["dc.identifier.issn","1080-6040"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78338"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Antimicrobial-Resistant Bacteria in Infected Wounds, Ghana, 20141"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","889"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","893"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Fabri, Mario"],["dc.contributor.author","Schlapbach, Christoph"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2020-12-10T18:27:20Z"],["dc.date.available","2020-12-10T18:27:20Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1111/ddg.13925_g"],["dc.identifier.eissn","1610-0387"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76313"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Diagnose mykobakterieller Hautinfektionen"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3300"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Epidemiology and Infection"],["dc.bibliographiccitation.lastpage","3304"],["dc.bibliographiccitation.volume","144"],["dc.contributor.author","Gerhold, G."],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Gross, U."],["dc.contributor.author","Bohne, Wolfgang"],["dc.date.accessioned","2020-12-10T15:22:19Z"],["dc.date.available","2020-12-10T15:22:19Z"],["dc.date.issued","2016"],["dc.description.abstract","The increasing prevalence of extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria is a serious threat for current healthcare settings. In this study we investigated the molecular epidemiology of ESBL-producing E. coli at the University Medical Center Gottingen in Lower Saxony, Germany. All E. coli isolates with an ESBL phenotype were collected during a 6-month period in 2014. Multilocus sequence typing and CTX-M characterization were performed on 160 isolates. Of the ESBL-producing isolates 95.6% were CTX-M positive. Compared to recent Germany-wide studies, we found CTX-M-1 to occur in higher frequency than CTX-M-15 (44.4% vs. 34.4%). CTX-M-14 and CTX-M-27 were detected at 9.4% and 5.0%, respectively. The globally dominant sequence type (ST) 131, which is often associated with CTX-M- 15, occurred at a relatively low rate of 24%. Major non-ST131 sequence types were ST101 (5%), ST58 (5%), ST10 (4.4%), ST38 (4.4%), ST410 (3.8%) and ST453 (3.1%). Several of these major sequence types were previously shown to be associated with livestock farming. Together, our study indicates that E. coli lineage distribution in individual healthcare settings can significantly differ from average numbers obtained in nationwide studies."],["dc.identifier.doi","10.1017/S0950268816001412"],["dc.identifier.eissn","1469-4409"],["dc.identifier.isi","000388620000019"],["dc.identifier.issn","0950-2688"],["dc.identifier.pmid","27357252"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73355"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Cambridge Univ Press"],["dc.relation.issn","1469-4409"],["dc.relation.issn","0950-2688"],["dc.title","Multilocus sequence typing and CTX-M characterization of ESBL-producing E. coli : a prospective single-centre study in Lower Saxony, Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","595"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Medical Microbiology and Immunology"],["dc.bibliographiccitation.lastpage","602"],["dc.bibliographiccitation.volume","205"],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Voelker, Fabian M."],["dc.contributor.author","Lugert, Raimond"],["dc.contributor.author","Cooper, Paul"],["dc.contributor.author","Hasenclever, Kai"],["dc.contributor.author","Gross, Uwe"],["dc.contributor.author","Pfister, Herbert"],["dc.contributor.author","Silling, Steffi"],["dc.date.accessioned","2018-11-07T10:05:33Z"],["dc.date.available","2018-11-07T10:05:33Z"],["dc.date.issued","2016"],["dc.description.abstract","Data about the prevalence of human papillomaviruses (HPV) in African women with normal and abnormal cervical cytology are still scarce. Current HPV vaccines contain HPV types, which mainly represent the HPV epidemiology of industrial countries. As further developments of HPV vaccines are going on, it is necessary to regard regional differences in HPV type prevalence to ensure optimal protection by the vaccine. Vaginal swabs of Ghanaian pregnant women, routinely collected before delivery to rule out bacterial infections causing early onset sepsis, were screened for 12 high-risk (HR), 13 probably/possibly (pHR), and 18 low-risk (LR) HPV types. Most pregnant women come for delivery to the hospital. This was considered as appropriate possibility to have an unselected group of women. HPV DNA were detected in 55/165 women (33.3, 95 % CI 26.3-41.1 %). Thirty-four out of fifty-five (61.8, 95 % CI 47.7-74.3 %) of HPV-positive women were infected with HR and/or pHR HPV types. The five most prevalent HR or pHR HPV types were HPV-52 and HPV-67 (7 women each, 4.2, 95 % CI 1.9-8.9 %), HPV-53 (six women, 3.6, 95 % CI 1.5-8.1 %), HPV-45 (five women, 3.0, 95 % CI 1.1-7.3 %), and HPV-18 (four women, 2.4, 95 % CI 0.8-6.5 %), respectively. HPV-16 was found in two women only (1.2, 95 % CI 0.2-4.8 %). Future HPV vaccine research may devote special interest to HPV-67 and HPV-53 provided further studies confirm their high prevalence in the general population of Sub-Saharan African countries. The true carcinogenic potential of HPV-67, which is a member of species alpha9 including HPV-16, and so far categorized as pHR, should be clarified."],["dc.identifier.doi","10.1007/s00430-016-0475-9"],["dc.identifier.isi","000387361900008"],["dc.identifier.pmid","27601062"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38919"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-1831"],["dc.relation.issn","0300-8584"],["dc.title","High prevalence of human papillomaviruses in Ghanaian pregnant women"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1879"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Emerging infectious diseases"],["dc.bibliographiccitation.lastpage","1882"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Amuzu, Sylvarius K."],["dc.contributor.author","Ciman, Ring de"],["dc.contributor.author","Kassimova, Iparkhan"],["dc.contributor.author","Groß, Lisa"],["dc.contributor.author","Rabsch, Wolfgang"],["dc.contributor.author","Rosenberg, Ulrike"],["dc.contributor.author","Schulze, Marco"],["dc.contributor.author","Stich, August"],["dc.contributor.author","Zimmermann, Ortrud"],["dc.date.accessioned","2021-11-22T14:31:53Z"],["dc.date.available","2021-11-22T14:31:53Z"],["dc.date.issued","2011-10-01"],["dc.description.abstract","Bacterial distribution and antimicrobial drug resistance were monitored in patients with bacterial bloodstream infections in rural hospitals in Ghana. In 2001-2002 and in 2009, Salmonella enterica serovar Typhi was the most prevalent pathogen. Although most S. enterica serovar Typhi isolates were chloramphenicol resistant, all isolates tested were susceptible to ciprofloxacin."],["dc.description.sponsorship","Bayer Social Health Care Programs"],["dc.identifier.doi","10.3201/eid1710.110327"],["dc.identifier.fs","583995"],["dc.identifier.isi","000295897300014"],["dc.identifier.pmid","22000360"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7833"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/93412"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21848"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Centers Disease Control"],["dc.relation.issn","1080-6059"],["dc.rights.access","openAccess"],["dc.subject","Ghana; bacterial distribution; drug resistance"],["dc.subject.mesh","Adult"],["dc.subject.mesh","Anti-Bacterial Agents"],["dc.subject.mesh","Bacteremia"],["dc.subject.mesh","Drug Resistance, Bacterial"],["dc.subject.mesh","Ghana"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Microbial Sensitivity Tests"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Salmonella enterica"],["dc.subject.mesh","Time Factors"],["dc.subject.mesh","Typhoid Fever"],["dc.subject.mesh","Young Adult"],["dc.title","Bacteremia and antimicrobial drug resistance over time, Ghana."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","537"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Microorganisms"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Monnheimer, Mathieu"],["dc.contributor.author","Cooper, Paul"],["dc.contributor.author","Amegbletor, Harold K."],["dc.contributor.author","Pellio, Theresia"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Pfeifer, Yvonne"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2021-04-14T08:27:53Z"],["dc.date.available","2021-04-14T08:27:53Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3390/microorganisms9030537"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82438"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","2076-2607"],["dc.relation.orgunit","Institut für Krankenhaushygiene und Infektiologie"],["dc.rights","CC BY 4.0"],["dc.title","High Prevalence of Carbapenemase-Producing Acinetobacter baumannii in Wound Infections, Ghana, 2017/2018"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","150"],["dc.bibliographiccitation.journal","International Journal of Infectious Diseases"],["dc.bibliographiccitation.lastpage","159"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Blei, Claudia"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2022-12-01T08:30:37Z"],["dc.date.available","2022-12-01T08:30:37Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Candidemia is rare and has a high mortality rate. This study analyses the impact of bedside antifungal stewardship (AFS) on clinical management and prognosis of patients with candidemia at a university hospital in Germany. Methods: All patients with at least one positive blood culture with Candida species between 2014 and 2016 received bedside AFS with standardized recommendations. Medical records were retrospectively an- alyzed. Results from the intervention period from 2014-2016 (n=109), with focus on 2016 (n=39), were compared with those from the pre-intervention period in 2013 (n=30). Results: Bedside AFS was performed in 24/35 (69%) surviving patients in 2016 within the first 3 days after diagnosis of candidemia. All surviving patients (n=35) in 2016 received antifungal treatment compared with 24/28 (86%) in 2013 (p=0.0344). Follow-up blood cultures were performed in 25/35 (71%) in 2016 compared with 10/25 (40%) in 2013 (p=0.0046). Survival in the intervention compared with the pre- intervention group did not differ significantly (p=0.58) one year after the diagnosis of candidemia was made. However, patients with candidemia often have multiple serious comorbidities. Conclusions: Individualized bedside AFS significantly improves adherence to recommendations for pa- tients with Candida fungemia, especially guideline-oriented diagnostics and therapy. Improving the prog- nosis of patients with candidemia remains a huge challenge for AFS."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1016/j.ijid.2022.03.054"],["dc.identifier.pii","S1201971222001916"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117935"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.issn","1201-9712"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","Impact of routine bedside infectious diseases service on clinical management and prognosis of patients with Candida fungemia – an example for Antifungal Stewardship at university level in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]